{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.7","upperLimit":"2.5","value":"1.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"description":"Progressive disease is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameters (LD) of target lesions, taking as reference the smallest sum LD recorded since treatment started, or a measurable increase in a non-target lesion, or the appearance of new lesions. Time to progression is the number of months from first treatment until the date of progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR.","id":"OG000","title":"Treatment (Single-agent Depsipeptide)"}],"paramType":"MEDIAN","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"Until disease progression - max of 48 months","title":"Time to Progression","type":"PRIMARY","unitOfMeasure":"months"}